Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 56.98

+1.1%

Nov 5 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who started this subject	12/15/2003 9:00:20 AM
From: WhatsUpWithThat	Read Replies (1) of 52153

MLNM News - does this belong here given their estimate of it cutting a year off their timetable? Co announces that, , based on the recommendation of an independent data monitoring committee and the notification of regulatory authorities, it is halting the control arm in the phase III APEX trial. This allows patients currently receiving dexamethasone the option to immediately crossover to Velcade for Injection therapy. The findings of a pre-specified interim analysis found a statistically significant improvement in time to disease progression -- the primary endpoint of the trial -- in patients receiving Velcade compared to patients receiving high-dose dexamethasone. "Data from this trial were previously scheduled to be available in 2005 and this accelerates our timetable by over a year."

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next